Krystal Biotech (KRYS) PT Lowered to $107 at H. C. Wainwright, Buy Rating Maintained Ahead of Vyjuvek Launch
Tweet Send to a Friend
H.C. Wainwright analyst Joseph Pantginis reiterates a Buy rating on Krystal Biotech (NASDAQ: KRYS) while lowering his price target to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
